Optimizing strategy for cervical cancer prevention in china: a comprehensive modeling analysis
Screening women aged 35-64 with VIA and vaccinating girls aged 9-14 with the bivalent HPV vaccine is currently the most suitable cervical cancer prevention strategy for China. In scenarios with larger budgets, more accurate screening methods and the 9-valent HPV vaccine could be introduced. Our study provides crucial evidence for cervical cancer prevention and control policy in China.
Authors
- Wenxi Tang (ORCID: https://orcid.org/0000-0002-3564-3626)
- Dachuang Zhou
- Yi Wang (ORCID: https://orcid.org/0000-0002-2067-5465)
- Di Zhang (ORCID: https://orcid.org/0000-0002-5028-051X)
- Kejia Zhou
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1186/s12962-025-00630-y
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Natural Science Foundation of China
- China Pharmaceutical University